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Abstract
This article focuses on the sessions in which basic science research was presented at the XVII
International AIDS Conference (AIDS 2008). It also provides an analysis of basic science issues
which generated significant discussion and debate at the conference and are likely to have
implications for future laboratory and clinical research. Data presented at AIDS 2008 confirmed
the speed with which HIV establishes latent viral reservoirs following infection and the resulting
challenges to viral eradication given how effectively HIV proviral RNA inserts itself into human
DNA within these reservoirs. Studies also raised questions about the source of residual viremia
and how these might be targeted by novel therapeutic approaches.
Discussion
HIV has become a chronic, manageable disease for most
patients in high-income countries, who can expect to live
near-normal lifespans at current standards of care. Two
major journal reports confirming this conclusion were
released on the eve of the conference and brought a new
focus to conference presentations on the basic biology
behind the HIV-human host interaction [1,2].
Residual viremia and the limits of HIV disease 
management
Several presentations at AIDS 2008 examined the limits of
medical management of HIV. The virus can be reduced to
levels undetectable by standard assays, yet a small residual
amount of virus remains, on the order of 1 copy of HIV
RNA per millilitre of plasma. The source of this residual
viremia is still the subject of debate, but its consequence is
certain. Patients who stop antiretroviral therapy (ART),
even after many years, usually see their viral loads
rebound to pre-treatment levels within a matter of weeks.
Absent viral eradication, ART is for life. The world is there-
fore faced with the need to administer decades of antiret-
roviral agents to 30 or 40 million people, with all the
expense and toxicity management issues that come with
such a massive undertaking.
Robert Siliciano (Johns Hopkins University, USA) sum-
marized a decade's worth of research in his presentation
on the origin of residual viremia [3]. Siliciano's own
observations have led him to infer that there is essentially
no ongoing viral replication during successful ART.
Instead, residual viremia comes from cells containing
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latent HIV DNA in their genomes. HIV becomes activated
along with the cells' own genes during the immune
response to disease.
There is no evolution in this latent population and thus
no emergence of drug resistance. ART can control the
residual infection indefinitely but it cannot eradicate it.
More frustrating yet, the residual viremia in about half of
all virologically suppressed patients seems cloned from a
handful of isolates. Siliciano argues that on a few occa-
sions, HIV becomes integrated into progenitor cells that
faithfully copy the HIV genes as they divide and differen-
tiate into mature immune cells such as monocytes and
lymphocytes. Viral production begins only when these
mature cells become activated.
In this context, the possibility of therapeutically eliminat-
ing all latent HIV or removing HIV that silently replicates
along with the human genome in progenitor cell lines is
remote. In a presentation, Anthony Fauci (National Insti-
tute of Allergy and Infectious Diseaes, USA) suggested a
form of "immunotherapy" - in addition to early treatment
and treatment intensification - as one strategy for gradu-
ally eliminating the latent reservoir [4]. While protected
by the most potent ART, anti-HIV immune responses
could be preserved and ultimately enhanced. Eventually,
they might be strong enough, and residual HIV low
enough, to allow for drug discontinuation without viral
rebound.
The first step toward developing a therapeutic strategy for
controlling latent HIV will be to understand more pre-
cisely how HIV proviral DNA integrates into human chro-
mosomal DNA and the factors inducing latency.
Kadreppa Sreenath (National Centre for Cell Science,
India) presented data supporting suppression of tran-
scription by SMAR1, a component of the cellular nuclear
protein matrix; SMAR1 maintains the genes' physical
structure as well as helping to regulate their activity [5].
SMAR1, induced in response to HIV infection, forms a
repressor complex with two other proteins that bind to
the long terminal repeat region at the terminus of the HIV
genome. HIV tat, together with the cells' own activation
factor NF-B, displaces this complex and triggers viral rep-
lication. This model yields hints of a therapeutic strategy,
involving either SMAR1 promotion or tat inhibition, but
this concept is still far from a concrete therapeutic appli-
cation.
The challenging speed of acute infection
The conference yielded multiple presentations of how
rapidly HIV takes over during acute infection. Eric Hunter
and Debrah Boeras (Emory University, USA) showed that
new sexually acquired HIV is usually very genetically
homogenous [6,7]. It arises from a minor variant present
in the donor's body. Presumably such HIV has special,
still undefined characteristics that make it more fit for
transmission.
Once in contact with a new host, HIV moves very quickly.
Yonatan Ganor (Institut Cochin, France) described the
results from his group's explant model of human foreskin.
[8] Cell-associated HIV was efficiently transmitted in this
model. The Langerhans cells on the inner foreskin became
infected with HIV and transferred the virus to the CD4+ T-
cells in the dermis within one hour of initial contact. In
contrast, transport from the outer foreskin was 10 times
less efficient. Cells in the outer foreskin's keratinized layer
could become infected but that layer kept the infection
from spreading inward. Also, the Langerhans cells in this
layer degraded HIV when they captured it rather than
transporting it live to the virus's primary target.
The role of mucosal dendritic cells, of which Langerhans
cells form a subset, in facilitating HIV infection has been
known for some time (Figure 1). Dendritic cells contain
surface receptors containing C-lectin, to which HIV phys-
ically adheres [9]. DC-SIGN is the most widely recognized
of these receptors, but there are a number of others.
Dendritic cells' normal function is to present foreign anti-
gen to the CD4+ T-cells, which then stimulate an immune
response. The dendritic cell first internalizes the C-lectin
Cells Playing a Role in Genital HIV Transmission Figure 1
Cells Playing a Role in Genital HIV Transmission. 
Source: Vanham, G.
Future promising microbicidal products: What to learn from 
the in vitro work (THSY0601), from Lederman, M Offord, R 
and Hartly O. Microbicides and other topical strategies to 
prevent vaginal transmission of HIV. Nature Reviews Immu-
nology 6, 371-382 (1 May 2006)
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receptor-HIV complex in an endosome. Endosomes nor-
mally break up foreign bodies for antigen presentation.
Whether particular dendritic cell subsets actually degrade
or protect HIV depends on the structure of their C-lectin
receptors. This observation may help explain HIV's differ-
ent outcome on the inner and outer foreskin - and hence
the protective effect of circumcision [10].
Tove Kaldensjö (Karolinska Institute, Sweden) reported
on four different dendritic cell subsets present on the
female ectocervix [11]. Comparing HIV-negative women
with high and low risk for HIV exposure, Kaldensjö's team
found that the women with higher risk sexual behaviour
had more ectocervical dendritic cells with C-lectin recep-
tors capable of transporting HIV to lymphoid tissue.
Damage occurs very quickly once HIV starts infecting
CD4+ T-cells. Fauci noted that HIV establishes a latent
HIV reservoir in the first week after transmission. In addi-
tion, gastrointestinal effector CD4+ T-cells are virtually
eliminated during the first few weeks [12,13]. According
to a recent report by Fauci's group, CD4+ cell counts in gut
lymphoid tissue remain depressed even after 10 years of
suppressive ART, and this tissue represents the location of
most of the latent viral reservoir [14].
Understanding innate immunity and the role of toll-like 
receptors
Halting HIV's rapid progress during primary infection is
of prime importance. AIDS 2008 marked a new interest in
innate immunity, which is the first line of defence against
HIV. The initial inflammatory response arises from a vari-
ety of non-specific, T-cell independent immune responses
that recognize invasion by some sort of foreign material.
HIV's encounter with innate immunity starts with the C-
lectin receptors on mucosal dendritic cells. Though
mostly ignored until recently, innate immunity remains a
major factor throughout the HIV lifecycle.
Much of the new focus on innate immunity concerns toll-
like receptors (TLRs). TLRs are an ancient family of cell-
surface and internal receptors. They recognize molecules
that are common to many pathogens but foreign to host
cells. Present on human immune cells, including macro-
phages and lymphocytes, each receptor in the family spe-
cializes in recognizing a certain type of molecule - for
example, bacterial glycolipids or lipoproteins and viral
DNA or RNA. Once excited, TLRs start a signal cascade
that results in cell activation and the release of inflamma-
tory cytokines.
Research into the relationship between TLRs and HIV has
accelerated dramatically over the past five years. The AIDS
2008 Scientific Programme included several inconsistent,
and even conflicting, reports on strategies to employ TLRs
therapeutically.
Dumith Bou-Habib (Oswaldo Cruz Institute, Brazil)
reported on zymosan, a common fungal polysaccharide
that binds to TLR2. Zymosan inhibits HIV infection in
macrophages, apparently at the cell entry stage (Figure 2)
[15]. A synthetic compound, Pam3Cys has similar proper-
ties. However, Sandra Thibault (Research Centre in Infec-
tious Diseases, Canada) reported that Pam3Cys and other
compounds binding TLR2 and TLR5 on CD4+ T-cells
actually increase cellular HIV integration and production,
a result that conflicts with Bou-Habib's findings [16]. Ter-
rance Brann (SAIC-Frederick, Inc., USA) also presented
findings suggesting the HIV suppressive effects of TLRs.
His experiments were with a pair of TLR4 ligands pro-
duced by human neutrophils [17]. These molecules
reduced R5-tropic HIV replication in macrophage cultures
but did not affect X4-tropic HIV in CD4+ T-cells. In other
research, Leonid Margolis (National Institute of Child
Health, USA) discussed ways in which viral co-infections
such as HCV can up- and down-modulate HIV, probably
by interacting with various TLRs [18].
The inconsistencies in the studies presented require fur-
ther investigation. One explanation may be subtle ways in
which the TLR-signalled response directs chemokine and
cytokine release. The zymosan report, for example found
that macrophages respond to TLR2 stimulation by releas-
ing beta-chemokines, the chemotactic signalling mole-
cules that fit into and block the CCR5 receptor utilized by
R5-tropic HIV when entering new cells. T-cells respond to
TLR2 by producing NF-kB, as do macrophages, but with-
out the beta-chemokines.
The importance of the overall cell-signalling milieu was
further stressed in a report published just after the confer-
ence. It described the HIV suppressive effect of a mutation
in TLR8 [19]. The study, which included 782 HIV+
patients, observed that those with the mutant (A1G) gene
in TLR8 exhibited a mean CD4 decline that was 3.5-fold
slower than HIV+ patients with normal TLR8 (75% of the
total study population).
When stimulated, the mutant TLR8 triggers relatively
lower levels of NF-B and IL-10 and relatively higher lev-
els of tumour necrosis factor alpha (TNF-) as compared
with normal TLR8. All three are known to promote HIV
replication, but TLR8 stimulation and TNF- also activate
protective CD8+ cytotoxic lymphocytes and natural killer
(NK) cells [20].
NK cells are a type of white blood cell that non-specifically
kills virus-infected cells. At AIDS 2008, Samuel Nuvor
(University of Nairobi, Kenya) and colleagues argued thatJournal of the International AIDS Society 2009, 12(Suppl 1):S3 http://www.jiasociety.org/content/12/S1/S3
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down-regulation of NK cells is a critical difference
between HIV-1 infection and HIV-2, which progresses
more slowly [21]. Restoring NK cell activity via TLR8 or
otherwise might be an important component in therapeu-
tically or prophylactically creating an effective immune
response against HIV.
Harnessing the immune response
Stimulating the immune system to better fight HIV is a
complicated issue. Chronic immune system activation
without achieving effective HIV control may be a major
contributor to HIV-associated T-cell loss [22]. Immune
control and regeneration processes become exhausted or
dysfunctional. They fail to replace cells lost to HIV or even
cause more cells to die via a form of cell suicide known as
apoptosis. A number of the factors contributing to
immune decline were described at the conference. These
include loss of proliferative capacity and response to anti-
gen presentation in HIV-specific CD8+ cytotoxic lym-
phocytes [23,24].
Notably, a post-AIDS 2008 report described increased cel-
lular TLR levels and heightened responsiveness to TLR sig-
naling in persons with HIV [25]. This report implicates
TLRs in immune dysfunction during untreated HIV infec-
tion rather than as a source of protection.
Many of the conference presenters nonetheless suggested
that their research findings will eventually help to identify
ways to restore the immune response and devise new
means for controlling HIV. The relevance of these results
is not yet clear given the high degree of HIV control
achieved by direct antiretroviral therapy. Suppressing HIV
will by itself eliminate much of the chronic inflammation
The Toll-like Receptors in and on Cells Recognize Microbial Patterns and Trigger Immune Responses Figure 2
The Toll-like Receptors in and on Cells Recognize Microbial Patterns and Trigger Immune Responses. Source: 
Pimenta-Inada, H et al.
The Toll-like receptor 2 ligand Zymosan inhibits HIV-1 replication in human primary cells (MOAA0105), from Trinchieri G., 
Sher A., Nature Reviews Immunology March 2007, 7(3): 179-90
Journal of the International AIDS Society 2009, 12(Suppl 1):S3 http://www.jiasociety.org/content/12/S1/S3
Page 5 of 6
(page number not for citation purposes)
and allow immune recovery. The total CD4+ T-cell count
does not seem to ever return to pre-HIV levels, however,
and subtle defects in immune subpopulations remain
[26].
An obvious next step will be to better delineate what con-
stitutes effective anti-HIV immunity. Answering that ques-
tion is complicated by the fact that the behaviour of
individual immune components can have both positive
and negative effects. As the inconsistent TLR findings dis-
cussed previously suggest, researchers need to consider
how each component interacts with other aspects of the
immune system. Considering that HIV disease feeds on
immune activation, the ultimate goal is a plan for deploy-
ing the various immune defences to provide maximum
effectiveness with the least extraneous activity.
Manipulation of the immune system may eventually
prove useful in further restoring the immune system after
the antiretroviral agents have reduced HIV to undetectable
levels. In particular, enhancing the anti-HIV immune
response promises to help block residual HIV, perhaps
allowing for simplification or elimination of drug ther-
apy. In addition, immune therapy may prove more effec-
tive before the body ever comes in contact with HIV.
Vaccines and other preventive technologies have so far
been unable to block HIV transmission. Selectively stimu-
lating appropriate immune responses could prove vital to
advancing such prevention efforts.
Conclusion
The complexity and dynamism of HIV pathogenesis and
host/virus dynamics continue to present both new chal-
lenges and new opportunities for therapeutic interven-
tions. Studies at AIDS 2008 advanced our understanding
of the role of TLRs and other cellular mechanisms in the
inflammatory response to HIV, possible avenues for
manipulating the immune response to better control HIV
pathogenesis, and how the speed of acute infection and
ongoing residual viremia continue to present barriers to
the viral eradication. Conflicting data on the role of TLRs
in up or down-regulating HIV expression, and debate
regarding the source of residual viremia and potential
strategies on how to deal more effectively with viral reser-
voirs are important issues for the field that will need to be
addressed in future research.
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